immuno oncology frontiers world miami


Reg Waldeck

Reg Waldeck

Market Access Strategy Leader, Bayer

Reg Waldeck is an Oncology Market Access Strategy Leader at Bayer Pharmaceuticals in the US, where he leads Market Access and related activities for Bayer's prostate cancer franchise and development pipeline. Reg was formerly head of Market Access, Pricing, Health Economics at Celldex Therapeutics Inc., a biotechnology company developing targeted therapeutics in (immuno)-oncology. Prior to this, he was with Bristol-Myers Squibb for 15 years in various functions spanning Marketing, Access, Pricing, and HEOR. Dr. Waldeck has a PhD in Biophysical Chemistry from the University of Sydney, and completed a postdoc in Biophysics at Caltech (Pasadena, CA), as well as post-graduate certificates in Health Economics (Monash University, Australia) and Marketing (University of Connecticut, USA). 

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy